These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 15040040

  • 1. Fenofibrate for patients with asymptomatic primary biliary cirrhosis.
    Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K.
    World J Gastroenterol; 2004 Mar 15; 10(6):894-8. PubMed ID: 15040040
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
    Dohmen K, Tanaka H, Haruno M.
    Fukuoka Igaku Zasshi; 2013 Oct 15; 104(10):350-61. PubMed ID: 24511666
    [Abstract] [Full Text] [Related]

  • 3. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS, Khanna A, Walker LJ, Wong LL, Dyson JK, Jones DEJ.
    Dig Dis Sci; 2016 Oct 15; 61(10):3037-3044. PubMed ID: 27435324
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.
    Zhang Y, Li S, He L, Wang F, Chen K, Li J, Liu T, Zheng Y, Wang J, Lu W, Zhou Y, Yin Q, Xia Y, Zhou Y, Lu J, Guo C.
    Drug Des Devel Ther; 2015 Oct 15; 9():2757-66. PubMed ID: 26045661
    [Abstract] [Full Text] [Related]

  • 5. Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis.
    Dohmen K, Onohara SY, Harada S.
    Korean J Gastroenterol; 2021 Oct 25; 78(4):227-234. PubMed ID: 34697277
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
    Duan W, Ou X, Wang X, Wang Y, Zhao X, Wang Q, Wu X, Zhang W, Ma H, You H, Jia J.
    Rev Esp Enferm Dig; 2018 Sep 25; 110(9):557-563. PubMed ID: 29739227
    [Abstract] [Full Text] [Related]

  • 7. Additional fibrate treatment in UDCA-refractory PBC patients.
    Chung SW, Lee JH, Kim MA, Leem G, Kim SW, Chang Y, Lee HY, Yoon JS, Park JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Yoon JH.
    Liver Int; 2019 Sep 25; 39(9):1776-1785. PubMed ID: 31162879
    [Abstract] [Full Text] [Related]

  • 8. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
    Ding D, Ren P, Guo G, Liu Y, Yang C, Zheng L, Jia G, Deng J, Sun R, Wang X, Zhou X, Shang Y, Han Y.
    Gastroenterol Hepatol; 2023 Nov 25; 46(9):692-701. PubMed ID: 36632973
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy.
    Han XF, Wang QX, Liu Y, You ZR, Bian ZL, Qiu DK, Ma X.
    J Dig Dis; 2012 Apr 25; 13(4):219-24. PubMed ID: 22435507
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
    Ding D, Guo G, Liu Y, Zheng L, Jia G, Deng J, Sun R, Wang X, Guo C, Shang Y, Han Y.
    Hepatol Commun; 2022 Dec 25; 6(12):3487-3495. PubMed ID: 36213941
    [Abstract] [Full Text] [Related]

  • 11. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
    Cheung AC, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield GM, Janssen HL, Feld JJ.
    Aliment Pharmacol Ther; 2016 Jan 25; 43(2):283-93. PubMed ID: 26559762
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial.
    Liu Y, Guo G, Zheng L, Sun R, Wang X, Deng J, Jia G, Yang C, Cui L, Guo C, Shang Y, Han Y.
    Am J Gastroenterol; 2023 Nov 01; 118(11):1973-1979. PubMed ID: 36892506
    [Abstract] [Full Text] [Related]

  • 13. Novel Therapies on Primary Biliary Cirrhosis.
    Czul F, Levy C.
    Clin Liver Dis; 2016 Feb 01; 20(1):113-30. PubMed ID: 26593294
    [Abstract] [Full Text] [Related]

  • 14. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R.
    Hepatology; 1998 Aug 01; 28(2):296-301. PubMed ID: 9695990
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
    Lee YM, Kaplan MM.
    Am J Gastroenterol; 2003 Jan 01; 98(1):205-8. PubMed ID: 12526960
    [Abstract] [Full Text] [Related]

  • 16. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH, Lindor KD.
    Expert Opin Pharmacother; 2016 Sep 01; 17(13):1809-15. PubMed ID: 27468093
    [Abstract] [Full Text] [Related]

  • 17. Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.
    Fang YQ, Lv DX, Jia W, Li J, Deng YQ, Wang Y, Yu M, Wang GQ.
    Medicine (Baltimore); 2014 Oct 01; 93(20):e104. PubMed ID: 25365404
    [Abstract] [Full Text] [Related]

  • 18. Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis.
    Wang L, Sun K, Tian A, Liu Y, Zhang M, Zhou X, Han Y.
    Minerva Med; 2022 Dec 01; 113(6):974-982. PubMed ID: 33949176
    [Abstract] [Full Text] [Related]

  • 19. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
    Lemoinne S, Pares A, Reig A, Ben Belkacem K, Kemgang Fankem AD, Gaouar F, Poupon R, Housset C, Corpechot C, Chazouillères O.
    Clin Res Hepatol Gastroenterol; 2018 Dec 01; 42(6):521-528. PubMed ID: 30100231
    [Abstract] [Full Text] [Related]

  • 20. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD.
    Hepatology; 2000 Feb 01; 31(2):318-23. PubMed ID: 10655252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.